Study Study arms Population Primary outcome Estimated study completion
NCT01373216 Exenatide vs. no intervention 38 patients with type 2 diabetes undergoing elective aortocoronary bypass Cardiac function – echocardiographic parameters April 2014
NCT01254123 (EXAMI) [101, 102] Exenatide vs. placebo 40 patients with first acute myocardial infarction undergoing primary PCI Safety Unknown
NCT01144338 (EXSCEL) Exenatide vs. placebo 14,000 patients with type 2 diabetes Time to composite endpoint of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke April 2018
NCT01715428 Liraglutide 300 patients with type 2 diabetes Carotid intima-media thickness December 2015
NCT01179048 (LEADER) Liraglutide vs. placebo 9,340 patients with type 2 diabetes Time to composite endpoint of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke October 2015
NCT01595789 (AddHope2)[103] Liraglutide vs. placebo 40 patients with coronary artery disease and newly diagnosed type 2 diabetes Beta-cell function and left ventricular ejection fraction after 12 weeks October 2015
NCT01472640 (LIVE)[104] Liraglutide vs. placebo 240 patients with chronic heart failure with and without diabetes Change in left ventricular function December 2014
NCT01394952 (REWIND) Dulaglutide vs. placebo 9,622 patients with type 2 diabetes Time to first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke April 2019
NCT01147250 (ELIXA) Lixisenatide vs. placebo 6,000 patients with type 2 diabetes who recently experienced an acute coronary syndrome event Time to first occurrence of the primary cardiovascular event January 2015
ELIXA, Evaluation of Lixasenatide in Acute Coronary Syndrome; EXAMI, Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction; EXSCEL, Exenatide Study of Cardiovascular Event Lowering; GLP-1: glucagon-like peptide-1; LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; PCI, percutaneous coronary intervention; REWIND, Researching Cardiovascular Events with a Weekly Incretin in Diabetes
Table 2: Ongoing Trials of the Cardioprotective Effects of the GLP-1 Receptor Agonists.